AlphaCentric Advisors LLC Has $163,000 Stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

AlphaCentric Advisors LLC raised its position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 108.3% in the second quarter, HoldingsChannel.com reports. The fund owned 12,500 shares of the company’s stock after purchasing an additional 6,500 shares during the quarter. AlphaCentric Advisors LLC’s holdings in Viridian Therapeutics were worth $163,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently modified their holdings of the company. Ameritas Investment Partners Inc. raised its holdings in shares of Viridian Therapeutics by 19.2% in the 1st quarter. Ameritas Investment Partners Inc. now owns 4,961 shares of the company’s stock valued at $87,000 after purchasing an additional 799 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Viridian Therapeutics by 122.6% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,369 shares of the company’s stock valued at $182,000 after buying an additional 4,610 shares during the period. Principal Financial Group Inc. lifted its position in shares of Viridian Therapeutics by 9.7% in the first quarter. Principal Financial Group Inc. now owns 11,915 shares of the company’s stock valued at $209,000 after buying an additional 1,058 shares during the last quarter. New York State Common Retirement Fund boosted its stake in shares of Viridian Therapeutics by 9.7% during the 4th quarter. New York State Common Retirement Fund now owns 17,495 shares of the company’s stock worth $378,000 after acquiring an additional 1,545 shares during the period. Finally, Virtu Financial LLC acquired a new position in shares of Viridian Therapeutics during the 4th quarter worth approximately $424,000.

Viridian Therapeutics Price Performance

Shares of NASDAQ VRDN traded up $0.12 during midday trading on Monday, reaching $15.17. The company’s stock had a trading volume of 766,964 shares, compared to its average volume of 958,297. The company has a market cap of $968.18 million, a P/E ratio of -3.35 and a beta of 1.13. Viridian Therapeutics, Inc. has a fifty-two week low of $10.93 and a fifty-two week high of $24.18. The company has a debt-to-equity ratio of 0.05, a quick ratio of 15.82 and a current ratio of 15.82. The business’s 50 day moving average price is $14.31 and its two-hundred day moving average price is $15.27.

Viridian Therapeutics (NASDAQ:VRDN) last released its earnings results on Thursday, August 8th. The company reported ($1.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.87) by ($0.15). The company had revenue of $0.07 million for the quarter, compared to analyst estimates of $0.09 million. Viridian Therapeutics had a negative return on equity of 83.18% and a negative net margin of 79,185.77%. On average, analysts forecast that Viridian Therapeutics, Inc. will post -3.98 EPS for the current fiscal year.

Analysts Set New Price Targets

VRDN has been the subject of several research reports. LADENBURG THALM/SH SH downgraded Viridian Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, May 9th. HC Wainwright restated a “buy” rating and set a $27.00 target price on shares of Viridian Therapeutics in a research note on Thursday, August 15th. Wedbush reiterated an “outperform” rating and issued a $42.00 price target on shares of Viridian Therapeutics in a research note on Monday, July 29th. Needham & Company LLC reissued a “buy” rating and issued a $30.00 price target on shares of Viridian Therapeutics in a report on Tuesday, June 11th. Finally, The Goldman Sachs Group began coverage on Viridian Therapeutics in a report on Thursday, June 6th. They set a “buy” rating and a $23.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $31.20.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.